Caris Life Sciences, Inc.
CAI
$16.96
$0.825.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 33.98M | -68.09M | -186.99M | -279.05M | -273.44M |
| Total Depreciation and Amortization | 20.64M | 22.62M | 27.39M | 33.05M | 38.25M |
| Total Amortization of Deferred Charges | 13.45M | 12.77M | 14.07M | 13.43M | 7.41M |
| Total Other Non-Cash Items | 117.46M | 148.99M | 125.99M | 112.05M | 39.73M |
| Change in Net Operating Assets | -38.16M | -33.13M | 19.00M | -11.88M | -14.56M |
| Cash from Operations | 147.37M | 83.16M | -546.00K | -132.40M | -202.61M |
| Capital Expenditure | -23.91M | -16.26M | -13.46M | -8.19M | -9.40M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 0.00 | 0.00 | 0.00 |
| Cash from Investing | -23.91M | -16.26M | -13.46M | -8.19M | -9.40M |
| Total Debt Issued | 27.87M | 27.87M | 27.87M | 27.87M | 0.00 |
| Total Debt Repaid | -124.00K | -106.00K | -88.00K | -91.00K | -99.00K |
| Issuance of Common Stock | 535.58M | 536.10M | 532.51M | 532.01M | 2.75M |
| Repurchase of Common Stock | -18.70M | -18.66M | -18.24M | -1.68M | -22.00K |
| Issuance of Preferred Stock | 121.24M | 121.24M | 121.24M | 121.24M | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.34M | -1.44M | -1.47M | 3.66M | -1.16M |
| Cash from Financing | 664.53M | 664.99M | 661.82M | 683.00M | 1.47M |
| Foreign Exchange rate Adjustments | 116.00K | 130.00K | 158.00K | 80.00K | -1.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 788.10M | 732.01M | 647.97M | 542.49M | -210.54M |